𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Pharmacokinetics and metabolism of selegiline

✍ Scribed by Heinonen E H; Myllylä V; Sotaniemi K; Lammintausta R; Salonen J S; Anttila M; Savijärvi M; Kotila M; Rinne U K

Book ID
114782829
Publisher
John Wiley and Sons
Year
1989
Tongue
English
Weight
542 KB
Volume
80
Category
Article
ISSN
0001-6314

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Integrated pharmacokinetic and metabolic
Integrated pharmacokinetic and metabolic modeling of selegiline and metabolites after transdermal administration
✍ Shashank Rohatagi; Jeffrey S. Barrett; Kimberly E. Dewitt; Richard J. Morales 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 249 KB 👁 2 views

Selegiline (SEL) is a selective, irreversible inhibitor of MAO-B, used in the treatment of Parkinson's disease, either alone or as an adjunct to L-DOPA. Selegiline hydrochloride (HCl) undergoes significant first-pass metabolism following oral administration. Transdermal delivery avoids the first-pas

Pharmacokinetics and relative bioavailab
Pharmacokinetics and relative bioavailability of selegiline in healthy volunteers
✍ Iftekhar Mahmood; Jacqueline S. Marinac; Sandra Willsie; William D. Mason 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 557 KB

## Abstract Selegiline is beneficial to Parkinsonian patients as an adjunct to levodopa therapy. A sensitive fluorimetric assay based on ibhibition of rat brain monoamine oxidase‐B (MAO‐B) __in vitro__ has been developed to study the pharmacokinetics of selegiline. This method quantitates selegilin

The pharmacokinetics and absolute bioava
The pharmacokinetics and absolute bioavailability of selegiline in the dog
✍ Iftekhar Mahmood; David K. Peters; William D. Mason 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 532 KB

Selegiline is beneficial to Parkinsonian patients as an adjunct to levodopa therapy. Currently no pharmacokinetic data are available for selegiline in the literature, mainly due to lack of analytical methods that can measure concentrations below 10 ng mL-' in plasma. A sensitive fluorimetric assay b

Pharmacokinetic evaluation of a selegili
Pharmacokinetic evaluation of a selegiline pulsatile oral delivery system
✍ Shashank Rohatagi; Jeffrey S. Barrett; Kimberly E. Dewitt; Denis Lessard; Richar 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 440 KB

Selegiline is a selective, irreversible inhibitor of MAO-B, used in the treatment of Parkinson's disease, either alone or as an adjunct to L-DOPA. The sole recommended dosing regimen is 5 mg given in the morning and at noon with breakfast and lunch. A pulsatile oral dosage form was developed to mimi

Pharmacokinetics and metabolism of encai
Pharmacokinetics and metabolism of encainide
✍ Patrice Jaillon 📂 Article 📅 1990 🏛 Springer US 🌐 English ⚖ 404 KB

The metabolism of encainide occurs in the liver and is polymorphically distributed according to the same genetic factor that determines the 4-hydroxylation of debrisoquine. Over 90% of patients are extensive metabolizers (EM) in whom the oral bioavailability of encainide is only 30% because of exten